Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Sickle cell disease: Rehospitalization rates high

The largest study to date of the use of acute care medical services by people with sickle cell disease found four of every 10 had to return to the hospital within 30 days of a previous hospitalization or go to the emergency department for treatment of pain, according to a new study funded in part by HHS' Agency for Healthcare Research and Quality.

7 Apr 2010

Reverse Medical signs strategic partnership agreement with Getz Bros.

Reverse Medical Corporation today announced it has entered into a strategic partnership agreement with Getz Bros. & Company, Inc., for distribution of Reverse Medical devices throughout the Pacific Rim. Getz is an international marketing and medical distribution services company with over 50 offices in 24 countries around the world, and has an excellent reputation for global distribution.

7 Apr 2010

Research shows direct link between dental health and general health

Research has shown a direct link between the health of our mouths and our general health. Periodontal (gum) disease may increase adult risk of diseases such as heart, stroke, diabetes and respiratory diseases. Tooth and gum disease and is one of the most common dental problems of older adults.

7 Apr 2010

Accumetrics completes enrollment phase of GRAVITAS clinical trial

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.

7 Apr 2010

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.

6 Apr 2010

Antiarrhythmic drug dronedarone less effective and causes fewer side effects

In a rigorous new review of the antiarrhythmic drug dronedarone (Multaq), researchers at the Cedars-Sinai Heart Institute conclude that the controversial drug is only modestly effective and has no clear safety benefits.

6 Apr 2010

Alpha cells in pancreas can convert into insulin-producing beta cells: Study

Alpha cells in the pancreas, which do not produce insulin, can convert into insulin-producing beta cells, advancing the prospect of regenerating beta cells as a cure for type 1 diabetes. The findings come from a study at the University of Geneva, co-funded by the Juvenile Diabetes Research Foundation, that is published today in the online edition of the scientific journal Nature.

6 Apr 2010

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Cryo-Cell International, Inc. today announced results of a study published this month in the cover article of Stem Cells and Development showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders.

5 Apr 2010

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.

5 Apr 2010

Hospital ER wait time via text messaging

The first wave of Spring Breakers has hit the sugar white sands of Panama City Beach, Florida. While most don't plan on a trip to the emergency department while they're on vacation, some end up there. And when they need emergency care, Gulf Coast Medical Center has made it easy for vacationers to find out how long they may have to wait for treatment before they leave for the hospital.

5 Apr 2010

China's SFDA finds certain batches of Jiangsu Yanshen's human use rabies vaccine substandard

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that China's State Food and Drug Administration ("SFDA") issued a statement on its investigation into the human use rabies vaccine manufactured by Jiangsu Yanshen Biological Technology Stock Co., Ltd.. Simcere obtained a controlling stake in Jiangsu Yanshen on October 24, 2009.

5 Apr 2010

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the company will participate in a panel discussion on Personalized Medicine for the Treatment of Multiple Sclerosis on April 7, 2010.

5 Apr 2010

Inflammation has a role to play in premature births and brain injury: Sahlgrenska Academy thesis

Researchers have gone some way to explaining what happens during premature births and how brain injury develops in premature babies. New findings show that inflammation in both the amniotic fluid and the baby's brain has a role to play, reveals a thesis from the Sahlgrenska Academy.

5 Apr 2010

Research may help develop new ways to diagnose and treat communication disorders

An international research consortium has identified more than 800 genes that appear to play a role in the male zebra finch's ability to learn elaborate songs from his father. The researchers also found evidence that song behavior engages complex gene regulatory networks within the brain of the songbird- networks that rely on parts of the genome once considered junk.

5 Apr 2010

Researchers identify three new genetic variants that increase risk of intracranial aneurysms

In the largest genome-wide study of brain aneurysms ever conducted, an international team led by researchers at the Yale School of Medicine have identified three new genetic variants that increase a person's risk for developing this deadly disease.

5 Apr 2010

KMI receives 2-year Phase II SBIR grant to study new treatment for TBI

Kinetic Muscles Inc., a leading innovator of neurorehabilitation technology, announced it has received a 2-year Phase II SBIR grant to study a new treatment for veterans returning from active duty with traumatic brain injury.

5 Apr 2010

Implementing value-based insurance design programs in health care reform law

Value-based insurance design programs -- a concept created at the University of Michigan -- are part of the nation's new national health care plan, and U-M physician A. Mark Fendrick, M.D. is working with policy setters to implement the strategy.

3 Apr 2010

Young adults with hyperthyroidism face increase risk of stroke

Young adults with overactive thyroid face a 44 percent increased risk of stroke compared to those with normal thyroid function, according to a study reported in Stroke: Journal of the American Heart Association.

3 Apr 2010

Genome of Australian zebra finch decoded

Nearly all animals make sounds instinctively, but baby songbirds learn to sing in virtually the same way human infants learn to speak: by imitating a parent.

2 Apr 2010

CARF re-accredits Thomas Jefferson University Hospital's Comprehensive Acute Rehabilitation Unit

The Commission on Accreditation of Rehabilitation Facilities (CARF) International recently announced that the inpatient rehabilitation program and stroke specialty program of the Comprehensive Acute Rehabilitation Unit of the Department of Rehabilitation Medicine at Thomas Jefferson University Hospital have again been re-accredited for a period of three years. The accreditation extends through February 2013.

2 Apr 2010